Abstract
To explore interleukin-1 beta (IL-1 beta) and IL-6 gene polymorphism, and investigate the relationship between their gene polymorphism and the morbid state of patients with acute pancreatitis (AP). The polymorphism of IL-1 beta gene 511C/T and IL-6 gene 634C/G site was analyzed by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) in patients (74 patients) with AP, including mild acute pancreatitis (MAP, 36 patients) and severe acute pancreatitis (SAP, 38 patients), and also a group of normal control (78 patients). The plasma concentrations of IL-1 beta and IL-6 were measured by enzyme linked immunosorbent assay (ELISA). The patients with SAP were divided into groups on the basis of different genotypes, and the clinical data were compared among different groups. The plasma levels of IL-1 beta and IL-6 in patients with AP were significantly higher than normal control group [IL-1 beta: (13.16+/-2.82) ng/L vs. (6.21+/-1.57) ng/L; IL-6: (84.86+/-32.92) ng/L vs. (9.95+/-2.49) ng/L, both P<0.05]. There was no statistical significance between IL-1 beta gene 511 site and IL-6 gene 634 site genotype or allele frequency between the patients with AP and the normal control. In patients with SAP, IL-1 beta gene 511 site T/T genotype and T allele frequency were significantly higher than that of MAP group (both P<0.05). There was no statistically significant difference in plasma levels of IL-1 beta between C/C group and C/T+T/T group, and the plasma levels of IL-6 in patients with IL-6 gene 634 site C/G were significantly higher than C/C group [(97.23+/-35.49) ng/L vs. (72.14+/-24.55) ng/L, P<0.05]. In patients with SAP, the scores of clinical evaluation in IL-1 beta gene 511 site C/T+T/T group and IL-6 gene 634 site C/G group were significantly higher than that in IL-1 beta gene 511 site C/C group and IL-6 gene 634 site C/C group (all P<0.05). IL-1 beta gene 511 site C/T and IL-6 gene 634 site C/G polymorphism may be genetic susceptibility factors for exacerbation of AP.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
